PT  - JOURNAL ARTICLE
AU  - Egbelowo, Oluwaseun F.
AU  - Fox, Spencer J.
AU  - Gibson, Graham C.
AU  - Meyers, Lauren Ancel
TI  - Interpreting discordant SARS-CoV-2 diagnostic test results
AID  - 10.1101/2023.02.07.23285547
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.07.23285547
4099  - http://medrxiv.org/content/early/2023/02/10/2023.02.07.23285547.short
4100  - http://medrxiv.org/content/early/2023/02/10/2023.02.07.23285547.full
AB  - We introduce a model to interpret discordant SARS-CoV-2 test results and estimate that an individual receiving a positive rapid antigen test followed by a negative Nucleic Acid Amplification Test had only a 12-24% chance of being infected in the United States from March 2020 to May 2022.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the financial support from the National Institutes of Health (grant no. R01 AI151176) and the Centers for Disease Control and Prevention (grant no. U01IP001136). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://raw.githubusercontent.com/nytimes/covid-19-data/master/us-counties.csvI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present work are contained in the manuscript and available online at https://raw.githubusercontent.com/nytimes/covid-19-data/master/us-counties.csv https://raw.githubusercontent.com/nytimes/covid-19-data/master/us-counties.csv